Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type1 h9 @0 F3 t0 r Z9 P, a: A$ ~# S1 ~
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
) R1 t. M9 M+ @) I, V4 n+ Author Affiliations6 T1 w$ F" B3 R
' Q9 x. a- D1 X' W" A1 q* s, t+ ?
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) x' _( I+ i+ c. g4 G ~% t) J
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 h$ S- G c% P; F; q
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan * _" b5 h q. G% D
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
+ d/ d* s& ?0 A5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
; s$ o5 Y8 D+ D8 g+ F' s6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
p/ C5 ?% o' b _8 e7Kinki University School of Medicine, Osaka 589-8511, Japan 0 H3 d B1 W/ \+ z6 S
8Izumi Municipal Hospital, Osaka 594-0071, Japan 2 |9 M1 L9 a, I/ n6 S5 h' n9 a
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan & [" n" @0 R' q0 p
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
- \/ g% M6 c: E# z* l3 cAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
! L6 g( l' c8 j5 {# b! e, [: A8 r3 B
6 t4 x. E/ m6 Z9 I7 l. L |